CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation) (CHF-COVReduced)

Pr. Nicolas GIRERD

Status: Enrolling

Conditions: Reduced Ventricular Ejection Fraction; Chronic Heart Failure

Treatments: Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ); Procedure: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds; Procedure: Clinical examination centered on congestion; Procedure: Blood sample retrieved for biological assessment and biobanking; Other: Telephone follow-up

Study type: Interventional

Funder types: Other

Identifiers

NCT05089162

2020PI145-2

Details and patient eligibility

About

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COVReduced study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with reduced left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic acute heart failure with reduced ventricular ejection fraction admitted in hospital for scheduled day hospitalization or in consultation
• Patient with altered (left ventricular ejection fraction <40%) and moderately altered (left ventricular ejection fraction between 40 and 50%) left ventricular ejection fraction
• Age ≥18 years
• Patients having received complete information regarding the study design and having signed their informed consent form.
• Patient affiliated to or beneficiary of a social security scheme.

Exclusion criteria

• Comorbidity for which the life expectancy is ≤ 3 months
• Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion.
• History of lobectomy or pneumonectomy lung surgery
• Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.
• Pregnant woman, parturient or nursing mother
• Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
• Adult person who is unable to give consent
• Person deprived of liberty by a judicial or administrative decision,
• Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day

Experimental group

Treatment:

Other: Telephone follow-up

Procedure: Blood sample retrieved for biological assessment and biobanking

Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)

Procedure: Clinical examination centered on congestion

Procedure: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds